Latest news
Alzheimer’s Blood Tests Are Changing Decisions, Not Just Diagnoses
A randomised trial found that earlier disclosure of p-tau217 and neurofilament light results dramatically increased diagnostic certainty and changed management without increasing distress. Alzheimer’s blood biomarkers have crossed from accuracy into clinical utility.
Metabolic syndrome may leave a signature in mitochondrial DNA. The biomarker race should not outrun the evidence
IPM Brief – Issue 13 | The Test Is Becoming the Politics
Breast Cancer Gets a New PI3K Pathway Option.
Bladder Cancer Surgery Just Became a System Test
Down Syndrome Cannot Stay Outside Alzheimer’s Trials
Cataplexy Is Waiting on an FDA Clock
More Children Got A First Vaccine. Millions Still Fell Out Of The System.
AstraZeneca’s heart drug failure raises a brutal question: how much treatment is too much treatment?
Beans for men, broccoli for women? The real cardiometabolic warning is that risk starts by 22
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.